IPI/NIVO combo discussed by Mayo doctor

Key Points:
At 4 years, median overall survival was not reached in the nivolumab-plus-ipilimumab group, 36.9 months in the nivolumab group, and 19.9 months in the ipilimumab group. Median progression-free survival was 11.5 months, 6.9 months, and 2.9 months, respectively.

Yep, pretty impressive. The only downside is the incidence of grade 3 and 4 (combined) adverse events increases by about 30 per cent. So, the combo seems to be the way to go if your body can take it.

Hi Brian, here are two links, first shows 4 year survival and #'s for combination shows 53% survival down from 58% at 3 year mark in second link from New England journal of medicine. Nivo at 4 years survival is at 46% down from 52% at 3 year mark. https://www.businesswire.com/news/home/20181022005105/en/Opdivo-nivolumab-Combination-Yervoy-ipilimumab-Demonstrates-Durable

https://www.nejm.org/doi/full/10.1056/NEJMoa1709684

So four year survival for combo is 7% better than anti-Pd1 alone.  6% not as understated as I thought.  I guess I'm thinking more of the initial trial results.  I seem to remember the reported response rates being much greater for the combo than single agent but I could be wrong on that account also.  Seems to happen to me a lot these days.

Brian, the data always comes out in the fall a year behind checkmate 067 trial start time. I started in Jan. 2014 so just passed 5 year mark a month ago. I hope the survival curves have reached a point where they flatten out and stay where they are now. Take Care!!!Ed